GlaxoSmithKline plc company was founded in 1935 and is based in Brentford, the United Kingdom. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health related consumer products. The company offers prescription medicines to treat a range of conditions, such as infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets approximately 25 vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company offers OTC medicines, such as alli, a weight loss medicine; Panadol, a paracetamol/acetaminophen analgesic; smoking control products under the NicoDerm, NiQuitin CQ, Nicabate, and Nicorette names; and other brands, including Breathe Right nasal strips and Tums. Its oral healthcare products primarily comprise Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene, a treatment for dry mouth; and Polident, PoliGrip, and Corega, which are denture care cleansers and adhesives. Further, the company provides nutritional healthcare products, such as Lucozade, a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline operates in Europe, North America, Central and South America, the Caribbean, Asia, Australia, the Middle East, Africa, and the Southeast Asia.

Celsis International plc company was founded in 1992. Celsis International is all about playing it safe. Through the company's Product Group, it makes rapid diagnostic and monitoring systems used to detect and measure microbial contamination in consumer products and food. Its RapidScreen assays are used by makers of personal care goods, cosmetics, OTC drugs, and a variety of beverages. CellScan Innovate is used by dairy producers. The division, which accounts for little more than half of Celsis International's sales, counts among its customers Dow Corning and Gillette. Celsis Laboratory Group performs quality testing for the cosmetics, drug, and chemicals industries.

Mirus Bio provides gene transfer technologies to the pharmaceutical industry. The company's reagent kits assist researchers with in vitro transfection, in vivo delivery, DNA and RNA labeling, and RNA interference. Besides its kits, Mirus Bio is also developing its own therapies based on its intravenous technology, called Pathway IV, that facilitates the delivery of plasmid DNA to targeted muscles. One of those therapies is MyoDys, a gene therapy designed to treat muscular dystrophy by delaying loss of muscle function. Mirus Bio is also developing treatments for peripheral ischemia and anemia. Mirus Bio has agreed to be acquired by Roche Holding for $125 million.

Otsuka America is US headquarters of Japan's Otsuka Pharmaceutical. Otsuka America oversees pharmaceutical research and development, marketing, and distribution of both prescription drugs and over-the-counter (OTC) medicines. The holding company's pharmaceutical subsidiaries include Otsuka America Pharmaceutical (prescription drug marketing), Otsuka Maryland Medicinal Laboratories (research), Cambridge Isotope Laboratories (chemical ingredients), and Pharmavite (nutritionals). To help wash down its pills Otsuka America also holds consumer beverage makers Crystal Geyser (bottled water), Ridge Vineyards (wine), and Soma Beverage Company (specialty bottled water).

SomaLogic helps in the hunt for proteins. Its aptamer arrays bind to proteins in such a way that multiple protein targets can be identified at once. Life sciences researchers use the company's arrays to identify proteins related to angiogenesis (the formation of new blood vessels) and inflammation. Data gathered from this work could be used to develop new drugs and diagnostics for a variety of diseases. SomaLogic has partnered with Quest Diagnostics to develop diagnostics that can measure many proteins at once. As part of the arrangement, Quest Diagnostics made a $15 million investment in the company.

Sanofi-Aventis Deutschland boasts itself as one of the largest pharmaceutical businesses in the country. A subsidiary of French giant Sanofi-Aventis, the company manufactures and markets prescription and over-the-counter drugs. Along with its Lantus and Insuman insulin products, Sanofi-Aventis Deutschland produces Plavix and Lovenox. The company also dedicates much of its efforts on research and development at its Frankfurt, Germany headquarters and is focused on metabolic illnesses such as diabetes, as well as cancer and cardiovascular diseases.

Generex Biotechnology Corporation company was founded in 1983 and is based in Toronto, Canada. Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company's products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. Generex Biotechnology Corporation's under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum.

Network Biosystems develops high throughput DNA sequencing systems with applications in the personalized medicine, forensics, drug discovery, and security arenas. The company blends nanotechnology and mircrofluidics to achieve its DNA analysis. Its sequencing systems were conceived at MIT's Whitehead Institute. The company is in the developmental stage and is pursuing a variety of commercial applications including manufacturing a rugged portable STR analysis and identification in the forensics field and on site screening of large numbers for use by homeland security.

Aldagen's work stems from the need for tissue repair. The biopharmaceutical company develops cell regeneration therapies using adult stem cells. It uses a proprietary technology that isolates an enzyme known as aldehyde dehydrogenase, or ALDH, which it believes can target a number of diseases. Aldagen hopes its products will be used to treat hereditary metabolic diseases in children, leukemia, and cardiovascular diseases; all its drugs are in the development stage. The company does its own manufacturing and plans to do its own marketing. Venture capital firm Intersouth Partners holds about 42% of Aldagen, which filed an IPO in late 2009. The company is led by CEO W. Thomas Amick.

Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California. Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Pharmacyclics's products in clinical development includes HDAC Inhibitor for advanced solid tumors, recurrent lymphomas, and sarcoma; Factor VIIa Inhibitor for cancer therapy; B Cell Tyrosine Kinase Inhibitor for the treatment of B-Cell lymphomas, and autoimmune diseases and mast cell diseases; and MGd for primary brain tumor and childhood brain tumors. Its pre-clinical development products comprise B Cell Tyrosine Kinase Inhibitors for autoimmune disease and mast cell disease; and HDAC8 Inhibitors for the treatment of autoimmune and cancer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.